Medical Sciences Commons^™

Cellular Prostatic Acid Phosphatase (Cpacp) Serves As A Useful Biomarker Of Histone Deacetylase (Hdac) Inhibitors In Prostate Cancer Cell Growth Suppression., Yu-Wei Chou, Fen-Fen Lin, Sakthivel Muniyan, Frank C. Lin, Ching-Shih Chen, Jue Wang, Chao-Cheng Huang, Ming-Fong Lin

Journal Articles: Biochemistry & Molecular Biology

BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading cancer death in the United States, and also one of the major cancer-related deaths in Chinese. Androgen deprivation therapy (ADT) is the first line treatment for metastatic PCa. PCa ultimately relapses with subsequent ADT treatment failure and becomes castrate-resistant (CR). It is important to develop effective therapies with a surrogate marker towards CR PCa.

METHOD: Histone deacetylase (HDAC) inhibitors were examined to determine their effects in androgen receptor (AR)/cellular prostatic acid phosphatase (cPAcP)-positive PCa cells, including LNCaP C-33, C-81, C4-2 and C4-2B and MDA PCa2b …